» Articles » PMID: 29321666

Are There Multiple Cells of Origin of Merkel Cell Carcinoma?

Overview
Journal Oncogene
Date 2018 Jan 12
PMID 29321666
Citations 53
Authors
Affiliations
Soon will be listed here.
Abstract

Merkel cell carcinoma (MCC) is a rare but lethal cancer with the highest case-by-case fatality rate among all skin cancers. Eighty percent of cancers are associated with the Merkel cell polyomavirus (MCPyV). Twenty percent of MCCs are virus negative. Recent epidemiological data suggest that there are important, clinically relevant differences between these two subtypes of MCC. Recent studies in cancer genomics, mouse genetics, and virology experiments have transformed our understanding of MCC pathophysiology. Importantly, dramatic differences in the genetics of these two MCC subtypes suggest fundamental differences in their pathophysiology. We review these recent works and find that they provocatively suggest that MCPyV-positive and MCPyV-negative MCCs arise from two different cells of origin: the MCPyV-negative MCC from epidermal keratinocytes and the MCPyV-positive MCC from dermal fibroblasts. If true, this would represent the first cancer that we are aware of that evolves from cells of origin from two distinct germ layers: MCPyV-negative MCCs from ectodermal keratinocytes and MCPyV-positive MCCs from mesodermal fibroblasts. Future epigenetic experiments may prove valuable in confirming these distinct lineages for these MCC subtypes, especially for the clinical importance the cell of origin has on MCC treatment and prevention.

Citing Articles

Merkel Cell Polyomavirus Antibody in Tumor and Plasma Specimens in Patients with Merkel Cell Carcinoma.

Schmocker R, Nodit L, Ward A, Lewis J, McLoughlin J, Enomoto L Ann Surg Oncol. 2024; 32(1):464-473.

PMID: 39373930 DOI: 10.1245/s10434-024-16292-8.


The Role of the Large T Antigen in the Molecular Pathogenesis of Merkel Cell Carcinoma.

Myrda J, Bremm F, Schaft N, Dorrie J Genes (Basel). 2024; 15(9).

PMID: 39336718 PMC: 11431464. DOI: 10.3390/genes15091127.


Merkel cell carcinoma: updates in tumor biology, emerging therapies, and preclinical models.

Pedersen E, Verhaegen M, Joseph M, Harms K, Harms P Front Oncol. 2024; 14:1413793.

PMID: 39136002 PMC: 11317257. DOI: 10.3389/fonc.2024.1413793.


The small tumor antigen of Merkel cell polyomavirus accomplishes cellular transformation by uniquely localizing to the nucleus despite the absence of a known nuclear localization signal.

Thevenin K, Tieche I, Di Benedetto C, Schrager M, Dye K Virol J. 2024; 21(1):125.

PMID: 38831469 PMC: 11149282. DOI: 10.1186/s12985-024-02395-x.


Merkel-cell carcinoma: ESMO-EURACAN Clinical Practice Guideline for diagnosis, treatment and follow-up.

Lugowska I, Becker J, Ascierto P, Veness M, Blom A, Lebbe C ESMO Open. 2024; 9(5):102977.

PMID: 38796285 PMC: 11145756. DOI: 10.1016/j.esmoop.2024.102977.


References
1.
Houben R, Shuda M, Weinkam R, Schrama D, Feng H, Chang Y . Merkel cell polyomavirus-infected Merkel cell carcinoma cells require expression of viral T antigens. J Virol. 2010; 84(14):7064-72. PMC: 2898224. DOI: 10.1128/JVI.02400-09. View

2.
Martincorena I, Roshan A, Gerstung M, Ellis P, Van Loo P, McLaren S . Tumor evolution. High burden and pervasive positive selection of somatic mutations in normal human skin. Science. 2015; 348(6237):880-6. PMC: 4471149. DOI: 10.1126/science.aaa6806. View

3.
Shuda M, Chang Y, Moore P . Merkel cell polyomavirus-positive Merkel cell carcinoma requires viral small T-antigen for cell proliferation. J Invest Dermatol. 2013; 134(5):1479-1481. PMC: 3989379. DOI: 10.1038/jid.2013.483. View

4.
Gore A, Li Z, Fung H, Young J, Agarwal S, Antosiewicz-Bourget J . Somatic coding mutations in human induced pluripotent stem cells. Nature. 2011; 471(7336):63-7. PMC: 3074107. DOI: 10.1038/nature09805. View

5.
Sauer C, Haugg A, Chteinberg E, Rennspiess D, Winnepenninckx V, Speel E . Reviewing the current evidence supporting early B-cells as the cellular origin of Merkel cell carcinoma. Crit Rev Oncol Hematol. 2017; 116:99-105. DOI: 10.1016/j.critrevonc.2017.05.009. View